VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

VIVOZON-UNAFRA-Inj

More Like This

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA

FDA Grants Breakthrough Therapy Designation to VERTANICAL's VER-01, a First-in-Class Non-Opioid Investigational Treatment for Chronic Low Back Pain

JOURNAVX bottle and tablet (Photo: Business Wire)

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

PR Newswire associated0

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures